Table 1.

Characteristics of the clinical trials included in the meta-analysis Child–Pugh class (A) and treatment (B)

A
Study	Age (year)	Child–Pugh class	Quality	Country
Fan et al (2001)20	Median: 48.2 (20–70)a	NR	H	China
Niguma et al (2005)22	59.8 vs 60.7	NR	M	Japan
Cheng et al (2005)26	47.8±14.3 vs 47.5±6.9	NR	M	China
Li et al (2006)23	Mean: 51.03 (33–78)a	NR	M	China
Liang et al (2008)21	44.61±11.33 vs 46.41±10.21	18:15 vs 37:16	H	China
Peng et al (2009)24	46.2±13.8 vs 50.2±7.5	44:7 vs 46:7	H	China
Zhou et al (2011)19	<50 12 vs 22	28:3 vs 27:11	M	China
	≥50 19 vs 16
Ma et al (2013)25	47.8±14.3 vs 47.5±6.9	84:3 vs 84:6	M	China
B
Study	Trial	Treatment	No of patients	Male/female
Fan et al (2001)20	NRCT	Surgery + TACE/HAI/PVI vs surgery	32 vs 79	NRa
Niguma et al (2005)22	NRCT	Surgery + arterial infusion chemotherapy vs surgery	6 vs 6	6:0 vs 4:2
Cheng et al (2005)26	NRCT	Surgery + TACE vs surgery	20 vs 7	17:3 vs 5:2
Li et al (2006)23	RCT	Surgery + TACE vs surgery	29 vs 52	100 vs 11a
		Surgery + TACE + PVC vs surgery	30 vs 52
Liang et al (2008)21	NRCT	Surgery + chemobiotherapy via portal vein vs surgery	33 vs 53	32:1 vs 48:5
Peng et al (2009)24	RCT	Surgery + TACE vs surgery	51 vs 53	46:5 vs 50:3
Zhou et al (2011)19	NRCT	Surgery + chemobiotherapy via portal vein vs surgery	31 vs 38	31:0 vs 35:3
Ma et al (2013)25	NRCT	Surgery + TACE vs surgery	87 vs 90	79:8 vs 81:9

Notes:

^aThe study only reported overall data. Data presented as mean±SD unless otherwise specified.

Abbreviations: H, high quality; HAI, hepatic artery infusion; M, medium quality; NR, not reported; NRCT, non-randomized controlled trial; PVC, portal vein chemotherapy/chemobiotherapy; PVI, portal vein infusion; RCT, randomized controlled trial; TACE, transarterial chemoembolization.